What is KPV derived from?

KPV is a tripeptide derived from the C-terminal end (amino acids 11-13) of alpha-melanocyte stimulating hormone (α-MSH). It retains the anti-inflammatory properties of α-MSH without its melanogenic (skin-darkening) effects.

How does KPV reduce inflammation?

KPV primarily works by inhibiting NF-κB, the master transcription factor that drives expression of inflammatory genes. By preventing NF-κB activation, KPV reduces production of multiple pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6.

Can KPV be taken orally?

Research has explored oral administration of KPV, particularly in nanoparticle formulations designed for targeted delivery to the gut. The tripeptide's small size is advantageous for oral bioavailability compared to larger peptides. However, no oral KPV products are approved for human use.

Is KPV researched for gut health?

Yes, KPV has been studied in inflammatory bowel disease models, showing reduction in intestinal inflammation and improvement in mucosal barrier function. Nanoparticle delivery systems have been developed to target KPV to inflamed gut tissue.

Does KPV cause skin darkening like Melanotan?

No. Unlike its parent molecule α-MSH and related compounds like Melanotan II, KPV does not bind melanocortin receptors responsible for melanogenesis. Its anti-inflammatory effects are melanocortin receptor-independent.

KPV has limited human safety data. Preclinical research suggests good tolerability, and the parent molecule α-MSH is a naturally occurring peptide. However, as an unregulated research compound, its safety profile in humans is not fully established.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 22 February 2026

Share:X Post LinkedIn

Immune & Inflammatory•Updated 2026-02-22•5 min read

What Is KPV? Benefits, Research & Safety

An anti-inflammatory tripeptide derived from alpha-MSH, researched for potent NF-κB inhibition and applications in gut and skin inflammation.

Share:X Post LinkedIn

Also known as:

Lys-Pro-Val

Alpha-MSH Fragment

KPV Tripeptide

DAnimal/cell evidence onlyUK: Sold as 'research only' (UK)WADA: Sport status unclear

UK summary: Not a licensed UK medicine. Tripeptide fragment of alpha-MSH with anti-inflammatory activity in animal IBD / colitis models. No human therapeutic use; UK IBD pathways do not include KPV.

Quick Facts

Overview

KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH). Despite being only three amino acids long, KPV retains the potent anti-inflammatory properties of its parent molecule while lacking the melanogenic (skin-darkening) effects. KPV exerts its anti-inflammatory effects primarily through inhibition of NF-κB—the master transcription factor driving inflammatory gene expression. This mechanism makes it relevant to a wide range of inflammatory conditions, with particular research interest in inflammatory bowel disease (IBD) and inflammatory skin conditions. The peptide's small size offers potential advantages for delivery, including oral and topical administration routes that are challenging for larger peptides. Research has explored KPV in nanoparticle formulations for targeted delivery to inflamed tissues. KPV is classified as a research peptide and is not approved for human therapeutic use. All information is for educational purposes based on published research.

Evidence standards summary

KPV — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

Not a licensed UK medicine. Tripeptide fragment of alpha-MSH with anti-inflammatory activity in animal IBD / colitis models. No human therapeutic use; UK IBD pathways do not include KPV.

02Human evidence grade

ETheoretical / insufficientStrength of evidence from published human trials.

03Preclinical evidence grade

CLimited human evidenceAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Unlicensed research peptide. Not approved for human therapeutic use by the MHRA.
EU: Not approved by the EMA. Available as a research compound.
Notes: KPV is not approved for therapeutic use in any major jurisdiction. Research use only.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Treats inflammatory bowel disease (Crohn's, ulcerative colitis).
Heals leaky gut and food sensitivities.
Treats psoriasis and eczema topically.
Safe oral peptide with no side effects.

07Common internet claims

Marketed by 'functional medicine' practitioners for gut healing.
Sold by online retailers in oral capsule and topical formats.
Promoted as a natural anti-inflammatory tripeptide.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Cures IBD / Crohn's / ulcerative colitis”	D	No	High	Animal-model anti-inflammatory effects; no UK-licensed indication; established IBD treatments have decades of human evidence.
“Heals leaky gut”	E	No	High	‘Leaky gut’ is not a recognised UK clinical diagnosis in the form usually marketed; KPV is not a licensed treatment for any GI condition.

09Safety uncertainty score

Moderate

Safety profile partly characterised; some signals from observational or preclinical data.

10Known adverse signals

Limited systematic safety data in humans.
Theoretical risk of suppressing helpful immune responses.
Unknown effects when used with biologics or immunosuppressants.
Topical preparation quality (compounding) unverified.

11Drug-interaction uncertainty

Moderate

Some interaction data published; check with a prescriber for your specific medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Sold as 'research only' (UK)

Unlicensed research peptide. Not approved for human therapeutic use by the MHRA.

Read the full UK legal guide → Research peptides and UK law

14EU legal position

Not approved by the EMA. Available as a research compound.

15What this page cannot tell you

Whether a UK-purchased KPV product contains the tripeptide at the labelled concentration.
Whether oral administration produces meaningful systemic exposure.
How it interacts with biologics (anti-TNF) or steroids used in IBD.
Whether the anti-inflammatory effect translates from cell culture to clinical disease.

16Last reviewed

Last reviewed: 22 February 2026

Next review due: 22 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

CLimited human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

No registered Phase 2 or 3 trials for IBD or any human condition.
Pharmacokinetic data in humans absent.
Long-term safety unstudied.
Combination safety with licensed IBD treatments uncharacterised.

19Safer alternatives / established care pathways

GP and gastroenterology referral for any persistent GI symptoms.
NHS IBD pathway — anti-TNF biologics, mesalazine, steroids — all with extensive evidence.
Dermatology referral for psoriasis or eczema, with licensed topical and biologic options.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is KPV a licensed UK medicine for IBD?
What licensed IBD or GI treatments should I consider first?
Should my GI symptoms be properly investigated?

Discovery & History

KPV was identified through structure-activity relationship studies of alpha-MSH, which sought to determine the minimal peptide sequence responsible for anti-inflammatory effects. Researchers discovered that the C-terminal tripeptide KPV (amino acids 11-13 of α-MSH) retained significant anti-inflammatory activity independent of melanocortin receptor binding. This finding was significant because it demonstrated that the anti-inflammatory and melanogenic properties of α-MSH could be separated, allowing anti-inflammatory applications without unwanted pigmentation effects. Research expanded through the 2000s and 2010s, with increasing focus on gut inflammation and targeted delivery systems.

Mechanism of Action

KPV's anti-inflammatory mechanism centres on NF-κB pathway inhibition: **NF-κB Inhibition** KPV enters cells and directly inhibits the NF-κB signalling cascade, preventing translocation of NF-κB to the nucleus. This reduces transcription of pro-inflammatory genes including TNF-α, IL-1β, IL-6, and other inflammatory mediators. **Cytokine Suppression** By blocking NF-κB, KPV reduces production of multiple pro-inflammatory cytokines simultaneously, providing broad anti-inflammatory effects rather than targeting a single mediator. **Melanocortin-Independent Effects** Unlike α-MSH, KPV does not require melanocortin receptor binding for its anti-inflammatory effects, suggesting direct intracellular mechanisms of action. **Mucosal Immune Modulation** In the gut, KPV has been shown to reduce inflammatory signalling in intestinal epithelial cells and immune cells, potentially supporting mucosal barrier integrity.

Researched Benefits

Based on preclinical and clinical research findings:

1
Potent NF-κB inhibition reducing inflammatory gene expression
2
Suppression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
3
Potential applications in inflammatory bowel disease (colitis models)
4
Anti-inflammatory effects in skin inflammation models
5
Small size enabling oral and topical delivery possibilities
6
Anti-inflammatory activity without melanogenic side effects

Claim vs Evidence

How popular claims about KPV stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Cures IBD / Crohn's / ulcerative colitis”	D	No	High	Animal-model anti-inflammatory effects; no UK-licensed indication; established IBD treatments have decades of human evidence.
“Heals leaky gut”	E	No	High	‘Leaky gut’ is not a recognised UK clinical diagnosis in the form usually marketed; KPV is not a licensed treatment for any GI condition.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	Research protocols vary; oral and injectable routes studied
Frequency	Daily administration in most research protocols
Duration	Typically 2-4 weeks in preclinical studies
Notes	Nanoparticle formulations studied for targeted gut delivery. No established human dosing protocols exist.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection
Oral (research)
Topical (research)
Nanoparticle delivery (research)

Half-Life	Stability
Short half-life typical of small peptides; exact pharmacokinetic data limited	Relatively stable for a tripeptide; lyophilised form recommended for storage

Safety Profile & Known Risks

Commonly Reported Side Effects

Injection site reactions (injectable route)
Limited human safety data available

Rare Risks & Concerns

Unknown long-term effects
Potential immune suppression with chronic use

Contraindications

Active infections (theoretical)
Immunocompromised states
Pregnancy and breastfeeding

UK & EU Regulatory Context

🇬🇧 United Kingdom

Unlicensed research peptide. Not approved for human therapeutic use by the MHRA.

🇪🇺 European Union

Not approved by the EMA. Available as a research compound.

KPV is not approved for therapeutic use in any major jurisdiction. Research use only.

Clinical Studies Summary

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

In conclusion, peptides represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks. Until longitudinal data clarify their safety and prevalence, peptide use in both competitive and recreational settings should be considered high-risk and ethically problematic.

J Sports Med Phys Fitness. 2026View on PubMed

Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.

Collectively, tripeptides represent a promising class of multifunctional bioactive molecules in wound care, offering novel avenues for targeted tissue regeneration. Future research should focus on improving their stability, bioavailability, and delivery systems to fully harness their clinical potential in regenerative medicine.

Int J Med Sci. 2025View on PubMed

Host defense peptides as a new drug lead to a strategy for inflammatory bowel disease.

HDPs have immunoregulatory mechanisms, downregulating the nuclear factor kappa B (NF-κB) pathway, modulating cytokine release, and restoring homeostasis. The data suggest that HDPs have therapeutic potential for IBDs, offering a way to reduce side effects, and we focus on this issue here.

Drug Discov Today. 2025View on PubMed

Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.

KdPT, a derivative of KPV corresponding to IL-1β(193-195), currently is emerging as another tripeptide with potent anti-inflammatory effects.

Adv Exp Med Biol. 2010View on PubMed

Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.

KdPT, a derivative of KPV corresponding to amino acids 193-195 of IL-1beta, is also emerging as a tripeptide with antiinflammatory effects. The physiochemical properties and expected low costs of production render both agents suitable for the future treatment of immune-mediated inflammatory skin and bowel disease, fibrosis, allergic and inflammatory lung disease, ocular inflammation, and arthritis.

Endocr Rev. 2008View on PubMed

New insights into the functions of alpha-MSH and related peptides in the immune system.

These effects were mediated via IL-10 production, because IL-10 knockout mice were resistant to alpha-MSH treatment. Therefore, therapeutic application of alpha-MSH or related peptides (KPVs) as well as alpha-MSH/KPV-pulsed DCs may be a useful approach for the treatment of inflammatory, autoimmune, and allergic diseases in the future.

Ann N Y Acad Sci. 2003View on PubMed

Looking for KPV?

Source research-grade KPV from a trusted UK supplier — third-party tested with certificate of analysis.

View at Supplier

Frequently Asked Questions

Questions to ask a qualified clinician about KPV